trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'trastuzumab']
trastuzumab deruxtecan cuts risk of disease progression or death by 50% for patients with her2-low metastatic breast cancer. #asco22 
The American Journal of #ManagedCare is a peer-reviewed, indexed publication. https://t.co/I2WRhmhOVC offers news in health policy, disease states, and managed care.